The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide mai
about
Cost-effectiveness of bortezomib for multiple myeloma: a systematic reviewTotal cost comparison in relapsed/refractory multiple myeloma.Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.Efficient allocation of novel agents in multiple myeloma: a work in progressEvaluation of immunomodulatory drugs in multiple myeloma: single center experience.Multiple myeloma in the marrow: pathogenesis and treatments.Effect of thalidomide on the proliferation of hepatoma cells assessed by osteopontin levels in nude mice.Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare DatabaseRevlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma.Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma.Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.Empliciti (Elotuzumab): First SLAMF7 Antibody Therapy Approved for the Treatment of Patients with Previously Treated Multiple Myeloma.Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple MyelomaPomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma.Management of Multiple Myeloma and Usage of Bortezomib: Perspective from India and UkraineLenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.Trends in overall survival and costs of multiple myeloma, 2000-2014.Systematic review of the economic evaluations of novel therapeutic agents in multiple myeloma: what is the reporting quality?Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for newly diagnosed multiple myeloma in a single institution of China.Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.Medical decision analysis for first-line therapy of chronic myeloid leukemia.Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma.Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASP
P2860
Q28075297-9189DF09-20BE-477C-9566-8F73D337AD0AQ34088340-A62A5591-EEC7-4441-9664-6B07F19BF87AQ34539519-5DF7B488-CD8B-4482-88AA-00B4716698B3Q36565638-3B345776-A102-4FC4-BD6E-209A616BFFE8Q36625053-1E30C232-385B-4B3C-BE16-0A895330AD08Q36725401-346A763B-006C-41C3-835D-8AE22140C1C4Q36900631-37BAD89B-4C53-4B28-87E0-7DA326037421Q37066097-A68B603C-F718-4133-B4D9-2B27FE217B3BQ37237660-614A984F-9AFE-4068-A69F-EB74D30D97E0Q37237666-49B59FBD-8327-4811-AC04-6E77E150A20FQ37237690-81204822-8C9A-46BA-80A9-58C61E0557CDQ37237698-1CEB485F-5729-439B-8588-13AA2478693AQ37237708-A4A47733-2854-48B4-B92D-DBA6468AA5D2Q37237715-F0CD8BD5-CA59-4F8B-BFEA-B1CE6AFC0F2DQ37425782-10EA9C9E-E226-4B57-BDE3-EDF00C795377Q38450335-6DB0FD1A-6A28-4C61-8385-8F10A370F52EQ38779003-076AB585-6EB4-4DD2-9397-90954549561BQ38786919-7BC889B5-D89A-448B-9EE3-4D3A5F5E6433Q39292865-157BC20E-065A-4A82-929D-CA31E8227CEFQ40301879-9DF84F7C-A00E-4357-A207-117A86E34895Q41042198-9180C57A-329A-4822-9765-471EA76E40CAQ45029815-478195ED-D331-4481-9F12-71592A81F4BCQ46252693-34C82A2F-EF48-474D-A9D2-D8807C598B77Q51067504-C233E038-A9F6-4786-82E1-B61853A61804Q52564578-678D3128-0DCF-4857-A542-B3FF16A5264AQ52609413-0E53012C-CD5D-4003-8D98-5F25C75F6F19
P2860
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide mai
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The cost-effectiveness of init ...... th continuous lenalidomide mai
@ast
The cost-effectiveness of init ...... th continuous lenalidomide mai
@en
type
label
The cost-effectiveness of init ...... th continuous lenalidomide mai
@ast
The cost-effectiveness of init ...... th continuous lenalidomide mai
@en
prefLabel
The cost-effectiveness of init ...... th continuous lenalidomide mai
@ast
The cost-effectiveness of init ...... th continuous lenalidomide mai
@en
P2093
P2860
P1433
P1476
The cost-effectiveness of init ...... th continuous lenalidomide mai
@en
P2093
Abbie Ba-Mancini
Andrew Cakana
Caroline Korves
Deyanira Corzo
Helgi van de Velde
Hongliang Shi
Kristina Chen
Louis P Garrison
Mei Sheng Duh
P2860
P356
10.1634/THEONCOLOGIST.2011-0380
P577
2013-01-08T00:00:00Z